|
Update on access to recombinant factor VIII and recombinant factor IX for the treatment of haemophilia in Australia Members are aware that the Federal government announced on 30 August 2004 that it would fund its share of the cost of providing recombinant factor products to all people with haemophilia regardless of age and viral status. The Commonwealth government now recognises the risk that known and unknown viruses and agents may be transmitted through blood products and accepted the recommendations of experts that where safer alternatives are available for treatment these should be provided. |
